Article
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Scientific reports - 25 Jun 2018
Omoto Shinya, Speranzini Valentina, Hashimoto Takashi, Noshi Takeshi, Yamaguchi Hiroto, Kawai Makoto, Kawaguchi Keiko, Uehara Takeki, Shishido Takao, Naito Akira, Cusack Stephen
Abstract excerpt
Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses. In clinical trials, single doses of BXM profoundly decrease viral titers as well as alleviating influenza symptoms. Here, we characterize the impact on BXA susceptibility and replicative capacity of variant viruses...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
